| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 | |
| Balance Sheet Date | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | 2014-Mar-31 | 2013-Dec-31 | |
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | Q1-FY2014 | |
| Price to Sales | 8.63x | 5.76x | 3.81x | 2.94x | 938.24x | 677.41x | 164.10x | 99.79x | 18.09x | 11.95x | 14.88x | 10.08x | 15.45x | 14.39x | 14.90x | 18.41x | 47.98x | 47.11x | 80.08x | 77.27x | 98.77x | 50.13x | 35.54x | 21.04x | 37.09x | 15.91x | 18.39x | 18.24x | 24.22x | 104.53x | 87.60x | 28.22x | 9.01x | 10.33x | |||||||||||||||
| Price to Book | 15.35x | 10.24x | 4.18x | 2.35x | 44.60x | 12.97x | 9.75x | 7.32x | 20.49x | 10.60x | 10.45x | 6.16x | 11.40x | 8.78x | 8.21x | 10.73x | 18.60x | 15.94x | 19.73x | 15.46x | 17.35x | 9.55x | 8.91x | 5.92x | 12.13x | 10.98x | 11.12x | 8.59x | 6.66x | 17.61x | 11.65x | 5.49x | 3.89x | 3.99x | |||||||||||||||
| Price to Earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 306.83x | 113.92x | 39.51x | 55.27x | 180.70x | - | - | - | - | - | - | |||||||||||||||
| Price to Unlevered FCF | 45.60x | 30.43x | - | 167.28x | - | - | - | - | - | - | - | - | - | - | - | - | 55.95x | 44.10x | 51.67x | 41.79x | - | - | - | - | - | 16.68x | 16.59x | ||||||||||||||||||||||
| Debt to Asset Ratio | .64x | .62x | .57x | .94x | .83x | .62x | .48x | .72x | .62x | .52x | .48x | .56x | .40x | .37x | .36x | .42x | .42x | .41x | .41x | .09x | .12x | .11x | .12x | .15x | .30x | .33x | .40x | .50x | .15x | .10x | .10x | .20x | .22x | .22x | .26x | .33x | .26x | .31x | .22x | .17x | .17x | .10x | .11x | .10x | .09x | .06x | .06x | .13x | |
| Current Ratio | 4.86x | 4.87x | 5.15x | 6.09x | 6.74x | 4.65x | 8.31x | 3.73x | 3.95x | 6.69x | 6.60x | 4.71x | 2.92x | 3.37x | 3.01x | 2.47x | 2.62x | 2.69x | 3.51x | 12.90x | 7.92x | 7.37x | 5.90x | 6.89x | 2.73x | 2.81x | 2.31x | 1.85x | 6.37x | 8.68x | 10.16x | 3.87x | 3.63x | 3.83x | 3.26x | 2.87x | 3.53x | 3.34x | 4.70x | 6.67x | 6.47x | 12.03x | 9.09x | 11.49x | 13.07x | 19.81x | 15.45x | 8.47x | |